News | Radiation Therapy | May 31, 2019

RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform

Facility includes six linear accelerator testing vaults for RefleXion BgRT system

RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform

May 31, 2019 — RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward, Calif. The 50,000 square-foot facility includes six state-of-the-art linear accelerator testing vaults for the RefleXion machine and will house manufacturing, quality control, and a customer education center with a radiation oncology suite for clinical training.

The new facility, which is the third building on the company’s campus, took 11 months to complete and required over 12 million pounds of concrete. In conjunction with the City of Hayward, RefleXion held an official ribbon-cutting ceremony on May 22.

RefleXion’s biology-guided radiotherapy (BgRT) platform is the first, according to the company, to utilize the cancer itself to guide radiation delivery, even in tumors that are moving. The patented technology uses positron emission tomography (PET), the gold standard in cancer staging, one day enabling multiple tumors to continuously signal their location during treatment. PET uses a tracer drug that is accumulated by the tumors and produces emissions illuminating their locations. The RefleXion machine detects the emissions and immediately sends beamlets of radiation directly to the tumor to destroy it.

For more information: www.reflexion.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

News | Radiation Therapy | April 07, 2020
April 7, 2020 — An intern...
Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...